close

Fundraisings and IPOs

Date: 2011-10-19

Type of information: Grant

Company: Arsanis Biosciences (Austria)

Investors: Austrian Research Promotion Agency (Austria)

Amount: € 1.19 million

Funding type: grant

Planned used:

The grant will support the development of monoclonal antibody therapeutics against nosocomial infections. Arsanis Biosciences GmbH, based in Vienna, Austria, is a wholly owned subsidiary of Arsanis. This company was founded in the fall of 2010 by Dr. Eszter Nagy (former SVP of Research at Intercell), Dr. Tillman Gerngross (Co-founder and CEO of Adimab, and Co-founder and CSO of GlycoFi, a wholly owned subsidiary of Merck & Co. since 2006) and Errik Anderson (Co-founder and COO of Adimab). Arsanis is committed to the development of monoclonal antibody therapeutics against severe infectious diseases that cannot be controlled with currently available medical treatments. The Company’s major focus is on life threatening infections that: are caused by antibiotic resistant pathogens; occur in immune compromised patients; or are associated with high mortality in spite of low rates of antibiotic resistance. Using first-in-class monoclonal antibody discovery technologies that support the selection of highly potent antibodies with unique qualities, Arsanis is building a broad portfolio of infectious disease targets. 

Others:

* On October 19, 2011, Arsanis Biosciences GmbH, an early stage biotechnology company developing anti-infective human monoclonal antibodies, announced the award of a grant for the development of monoclonal antibody therapeutics against nosocomial infections from the Austrian Research Promotion Agency (Forschungs-Förderungs-Gesellschaft or “FFG”), the leading public funding agency for translational research in Austria. The support from FFG for the first
year is € 1.19 million; additional funding (up to 70% of the total budget of € 12.5 million for the program) is expected in the following three years.

Therapeutic area: Infectious diseases

Is general: Yes